Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Talazoparib | hsa00040 | Pentose and glucuronate interconversions | 3.53E-02 | 1 | O60701 | UGDH | More | | Talazoparib | hsa00051 | Fructose and mannose metabolism | 3.35E-02 | 2 | P60174, P04075 | TPI1, ALDOA | More | | Talazoparib | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Talazoparib | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Talazoparib | hsa00310 | Lysine degradation | 3.15E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Talazoparib | hsa00350 | Tyrosine metabolism | 3.40E-02 | 1 | P28332 | ADH6 | More | | Talazoparib | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Talazoparib | hsa00562 | Inositol phosphate metabolism | 4.28E-02 | 2 | Q14642, P19174 | INPP5A, PLCG1 | More | | Talazoparib | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Talazoparib | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Talazoparib | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Talazoparib | hsa00600 | Sphingolipid metabolism | 2.77E-02 | 3 | Q9BX95, Q8TCT0, P15289 | SGPP1, CERK, ARSA | More | | Talazoparib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 6.37E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | | Talazoparib | hsa00670 | One carbon pool by folate | 7.39E-04 | 3 | O95954, P04818, Q99707 | FTCD, TYMS, MTR | More | | Talazoparib | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Talazoparib | hsa00860 | Porphyrin and chlorophyll metabolism | 3.15E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Talazoparib | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Talazoparib | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.40E-04 | 3 | P78417, P28332, P11712 | GSTO1, ADH6, CYP2C9 | More | | Talazoparib | hsa00982 | Drug metabolism - cytochrome P450 | 8.40E-04 | 3 | P11712, P78417, P28332 | CYP2C9, GSTO1, ADH6 | More | | Talazoparib | hsa00983 | Drug metabolism - other enzymes | 1.64E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Talazoparib | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | | Talazoparib | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Talazoparib | hsa01230 | Biosynthesis of amino acids | 1.98E-02 | 3 | P60174, P04075, O75390 | TPI1, ALDOA, CS | More | | Talazoparib | hsa01240 | Biosynthesis of cofactors | 2.05E-02 | 2 | P36551, O60701 | CPOX, UGDH | More | | Talazoparib | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa01522 | Endocrine resistance | 1.49E-02 | 5 | P22694, Q02750, Q9UM47, P46527, P08069 | PRKACB, MAP2K1, NOTCH3, CDKN1B, IGF1R | More | | Talazoparib | hsa01523 | Antifolate resistance | 7.05E-04 | 3 | Q92820, P04818, P18054 | GGH, TYMS, ALOX12 | More | | Talazoparib | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Talazoparib | hsa03013 | RNA transport | 8.33E-06 | 14 | O14980, Q09161, P61326, P38919, Q9H307, P37198, Q7Z3B4, P35658, Q14152, P55884, O75822, Q14240, Q06787, P51114 | XPO1, NCBP1, MAGOH, EIF4A3, PNN, NUP62, NUP54, NUP214, EIF3A, EIF3B, EIF3J, EIF4A2, FMR1, FXR1 | More | | Talazoparib | hsa03020 | RNA polymerase | 3.00E-02 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | Talazoparib | hsa03040 | Spliceosome | 4.08E-05 | 12 | Q14562, O60508, P08579, P26368, Q13595, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, CDC40, SNRPB2, U2AF2, TRA2A, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Talazoparib | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Talazoparib | hsa03320 | PPAR signaling pathway | 4.55E-02 | 2 | O00767, Q02318 | SCD, CYP27A1 | More | | Talazoparib | hsa03450 | Non-homologous end-joining | 1.02E-03 | 2 | P78527, P13010 | PRKDC, XRCC5 | More | | Talazoparib | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04012 | ErbB signaling pathway | 1.90E-03 | 4 | P16333, Q13191, P19174, P01106 | NCK1, CBLB, PLCG1, MYC | More | | Talazoparib | hsa04014 | Ras signaling pathway | 1.64E-02 | 7 | Q02750, Q15389, P08069, P17252, P21359, P62879, P22694 | MAP2K1, ANGPT1, IGF1R, PRKCA, NF1, GNB2, PRKACB | More | | Talazoparib | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04060 | Cytokine-cytokine receptor interaction | 3.20E-02 | 3 | P37173, P78552, P80075 | TGFBR2, IL13RA1, CCL8 | More | | Talazoparib | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.02E-02 | 3 | P09341, P02775, Q13651 | CXCL1, PPBP, IL10RA | More | | Talazoparib | hsa04064 | NF-kappa B signaling pathway | 2.28E-03 | 11 | O00463, P14778, P01584, Q13077, Q16548, Q8WV28, P63279, P24522, Q8NHW4, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TRAF1, BCL2A1, BLNK, UBE2I, GADD45A, CCL4L2, CXCL1, CYLD | More | | Talazoparib | hsa04066 | HIF-1 signaling pathway | 1.49E-02 | 5 | P08069, P17252, Q15389, Q02750, P46527 | IGF1R, PRKCA, ANGPT1, MAP2K1, CDKN1B | More | | Talazoparib | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04070 | Phosphatidylinositol signaling system | 1.53E-02 | 2 | Q86XP1, Q96DU7 | DGKH, ITPKC | More | | Talazoparib | hsa04110 | Cell cycle | 3.67E-06 | 9 | Q9UBD5, P06493, O60566, P78527, Q14683, P30304, P33981, P42773, P01106 | ORC3, CDK1, BUB1B, PRKDC, SMC1A, CDC25A, TTK, CDKN2C, MYC | More | | Talazoparib | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | Talazoparib | hsa04144 | Endocytosis | 1.13E-03 | 14 | Q13191, P0DMV8, P11142, Q9H444, O75351, P62491, P25024, Q96B97, P43250, Q15438, Q14161, P14784, Q9UMY4, Q9Y5X3 | CBLB, HSPA1A, HSPA8, CHMP4B, VPS4B, RAB11A, CXCR1, SH3KBP1, GRK6, PSCD1, GIT2, IL2RB, SNX12, SNX5 | More | | Talazoparib | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04213 | Longevity regulating pathway - multiple species | 2.61E-04 | 7 | P08069, Q9Y4H2, Q08828, P51828, P0DMV8, P11142, Q13547 | IGF1R, IRS2, ADCY1, ADCY7, HSPA1A, HSPA8, HDAC1 | More | | Talazoparib | hsa04218 | Cellular senescence | 1.70E-02 | 4 | P01889, P10321, P05141, P12236 | HLA-B, HLA-C, SLC25A5, SLC25A6 | More | | Talazoparib | hsa04270 | Vascular smooth muscle contraction | 9.46E-04 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | Talazoparib | hsa04310 | Wnt signaling pathway | 2.60E-02 | 3 | O15169, P17612, P67870 | AXIN1, PRKACA, CSNK2B | More | | Talazoparib | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Talazoparib | hsa04340 | Hedgehog signaling pathway | 2.62E-02 | 2 | O43791, P30279 | SPOP, CCND2 | More | | Talazoparib | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Talazoparib | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | | Talazoparib | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04530 | Tight junction | 2.45E-03 | 6 | Q8TEU7, P16989, P56750, O00501, Q14247, P24844 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN, MYL9 | More | | Talazoparib | hsa04540 | Gap junction | 2.03E-02 | 4 | P17252, P22694, P68371, Q02750 | PRKCA, PRKACB, TUBB2C, MAP2K1 | More | | Talazoparib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Talazoparib | hsa04612 | Antigen processing and presentation | 6.19E-03 | 8 | P48382, P26715, P26717, Q13241, O43908, P01732, P11142, P01375 | RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, HSPA8, TNF | More | | Talazoparib | hsa04613 | Neutrophil extracellular trap formation | 6.58E-04 | 7 | P19174, P11215, Q13547, Q93077, P62807, O60814, P68431 | PLCG1, ITGAM, HDAC1, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Talazoparib | hsa04621 | NOD-like receptor signaling pathway | 2.27E-02 | 9 | Q9H1Y0, P43490, O00463, Q05823, P01375, P49913, P59665, P59666, P12838 | ATG5, PBEF1, TRAF5, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Talazoparib | hsa04623 | Cytosolic DNA-sensing pathway | 1.65E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | | Talazoparib | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | | Talazoparib | hsa04640 | Hematopoietic cell lineage | 4.95E-02 | 3 | P01730, P06127, P09564 | CD4, CD5, CD7 | More | | Talazoparib | hsa04650 | Natural killer cell mediated cytotoxicity | 9.38E-04 | 11 | P01375, O60880, P20963, Q29983, P10321, P01889, Q13241, P26718, O75015, P26717, P26715 | TNF, SH2D1A, CD247, MICA, HLA-C, HLA-B, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Talazoparib | hsa04657 | IL-17 signaling pathway | 1.88E-03 | 6 | O00463, Q16539, P49841, P09341, P14780, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, TNF | More | | Talazoparib | hsa04658 | Th1 and Th2 cell differentiation | 2.71E-02 | 5 | P07766, P06239, Q9UL17, P14784, Q13761 | CD3E, LCK, TBX21, IL2RB, RUNX3 | More | | Talazoparib | hsa04659 | Th17 cell differentiation | 4.13E-03 | 7 | P06239, P14784, P14778, Q9UL17, Q13485, P08238, P07766 | LCK, IL2RB, IL1R1, TBX21, SMAD4, HSP90AB1, CD3E | More | | Talazoparib | hsa04662 | B cell receptor signaling pathway | 2.54E-04 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Talazoparib | hsa04664 | Fc epsilon RI signaling pathway | 1.07E-04 | 7 | P01375, Q16539, P42338, Q9UQC2, P07948, P09917, P20292 | TNF, MAPK14, PIK3CB, GAB2, LYN, ALOX5, ALOX5AP | More | | Talazoparib | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | Talazoparib | hsa04720 | Long-term potentiation | 5.41E-04 | 7 | P17252, Q15418, P51812, P18848, P17612, P22694, Q02750 | PRKCA, RPS6KA1, RPS6KA3, ATF4, PRKACA, PRKACB, MAP2K1 | More | | Talazoparib | hsa04723 | Retrograde endocannabinoid signaling | 2.60E-02 | 3 | P48169, P62873, P17612 | GABRA4, GNB1, PRKACA | More | | Talazoparib | hsa04724 | Glutamatergic synapse | 3.88E-04 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | Talazoparib | hsa04725 | Cholinergic synapse | 2.43E-04 | 10 | P17612, P22694, P17252, P62873, P62879, P63218, P50151, P18848, P42338, Q02750 | PRKACA, PRKACB, PRKCA, GNB1, GNB2, GNG5, GNG10, ATF4, PIK3CB, MAP2K1 | More | | Talazoparib | hsa04726 | Serotonergic synapse | 2.43E-02 | 4 | P22694, P17252, P62879, Q02750 | PRKACB, PRKCA, GNB2, MAP2K1 | More | | Talazoparib | hsa04727 | GABAergic synapse | 2.27E-05 | 10 | P62873, P62879, P63218, P50151, P48169, P15104, P17612, P22694, O60296, P17252 | GNB1, GNB2, GNG5, GNG10, GABRA4, GLUL, PRKACA, PRKACB, TRAK2, PRKCA | More | | Talazoparib | hsa04728 | Dopaminergic synapse | 1.36E-02 | 4 | P17612, P62873, P18848, O15516 | PRKACA, GNB1, ATF4, CLOCK | More | | Talazoparib | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04740 | Olfactory transduction | 2.09E-02 | 2 | P62873, P17612 | GNB1, PRKACA | More | | Talazoparib | hsa04742 | Taste transduction | 3.78E-03 | 2 | P48169, P17612 | GABRA4, PRKACA | More | | Talazoparib | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.01E-02 | 4 | P01584, Q08828, P51828, P0DP23 | IL1B, ADCY1, ADCY7, CALM1 | More | | Talazoparib | hsa04910 | Insulin signaling pathway | 1.67E-02 | 3 | Q14642, Q13191, Q9Y4H2 | INPP5A, CBLB, IRS2 | More | | Talazoparib | hsa04913 | Ovarian steroidogenesis | 1.16E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa04915 | Estrogen signaling pathway | 3.17E-02 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | | Talazoparib | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | | Talazoparib | hsa04926 | Relaxin signaling pathway | 5.70E-03 | 5 | P42338, P63218, P50151, P49767, P49407 | PIK3CB, GNG5, GNG10, VEGFC, ARRB1 | More | | Talazoparib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | | Talazoparib | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | Talazoparib | hsa04932 | Non-alcoholic fatty liver disease | 1.39E-02 | 6 | O43521, O75460, P01584, P13073, P12074, O95298 | BCL2L11, ERN1, IL1B, COX4I1, COX6A1, NDUFC2 | More | | Talazoparib | hsa04934 | Cushing syndrome | 1.98E-02 | 3 | P18848, P17612, O15169 | ATF4, PRKACA, AXIN1 | More | | Talazoparib | hsa04962 | Vasopressin-regulated water reabsorption | 7.22E-03 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | | Talazoparib | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Talazoparib | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Talazoparib | hsa04970 | Salivary secretion | 4.84E-03 | 6 | Q08828, P51828, P22694, P17252, P0DP23, P49913 | ADCY1, ADCY7, PRKACB, PRKCA, CALM1, CAMP | More | | Talazoparib | hsa04976 | Bile secretion | 4.78E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | | Talazoparib | hsa05010 | Alzheimer disease | 9.83E-03 | 7 | P13073, P18848, O15169, P67870, P05141, P12236, P28070 | COX4I1, ATF4, AXIN1, CSNK2B, SLC25A5, SLC25A6, PSMB4 | More | | Talazoparib | hsa05012 | Parkinson disease | 1.25E-02 | 6 | P13073, P05141, P12236, P17612, P18848, P28070 | COX4I1, SLC25A5, SLC25A6, PRKACA, ATF4, PSMB4 | More | | Talazoparib | hsa05016 | Huntington disease | 2.46E-02 | 9 | O95298, P13073, P12074, P24928, P30876, P62487, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, ERN1, PSMB4, PSMD12 | More | | Talazoparib | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | | Talazoparib | hsa05020 | Prion disease | 2.79E-04 | 9 | P17612, P13073, Q92736, P18848, P05141, P12236, P28070, O60282, P67870 | PRKACA, COX4I1, RYR2, ATF4, SLC25A5, SLC25A6, PSMB4, KIF5C, CSNK2B | More | | Talazoparib | hsa05022 | Pathways of neurodegeneration - multiple diseases | 4.48E-03 | 9 | P67870, P13073, Q06055, P18848, P05141, P12236, O15169, O15020, P28070 | CSNK2B, COX4I1, ATP5G2, ATF4, SLC25A5, SLC25A6, AXIN1, SPTBN2, PSMB4 | More | | Talazoparib | hsa05032 | Morphine addiction | 1.01E-02 | 3 | P17612, P62873, P48169 | PRKACA, GNB1, GABRA4 | More | | Talazoparib | hsa05034 | Alcoholism | 1.06E-05 | 9 | P17612, P18848, Q96RR4, P62873, Q93077, P62807, O60814, P84243, P68431 | PRKACA, ATF4, CAMKK2, GNB1, HIST1H2AC, HIST1H2BC, H2BC12, H3F3A, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Talazoparib | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Talazoparib | hsa05132 | Salmonella infection | 4.83E-02 | 2 | O00471, O60282 | EXOC5, KIF5C | More | | Talazoparib | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Talazoparib | hsa05134 | Legionellosis | 3.59E-04 | 6 | P01584, Q9NR31, P11215, P0DMV8, P11142, P19875 | IL1B, SAR1A, ITGAM, HSPA1A, HSPA8, CXCL2 | More | | Talazoparib | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | | Talazoparib | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Talazoparib | hsa05144 | Malaria | 3.76E-03 | 6 | P60033, P69905, P68871, P01375, P35443, P26718 | CD81, HBA2, HBB, TNF, THBS4, KLRK1 | More | | Talazoparib | hsa05146 | Amoebiasis | 4.55E-02 | 5 | P09341, P14778, P27930, O60603, P05089 | CXCL1, IL1R1, IL1R2, TLR2, ARG1 | More | | Talazoparib | hsa05150 | Staphylococcus aureus infection | 1.02E-03 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | Talazoparib | hsa05160 | Hepatitis C | 4.55E-02 | 3 | O00501, P29728, P01106 | CLDN5, OAS2, MYC | More | | Talazoparib | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | Talazoparib | hsa05163 | Human cytomegalovirus infection | 5.31E-05 | 20 | P01375, P01889, P10321, P62873, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P17612, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P18848, P04637, O00463 | TNF, HLA-B, HLA-C, GNB1, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, PRKACA, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, ATF4, TP53, TRAF5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | P67870 | CSNK2B | Casein kinase II subunit beta | P01889 | HLA-B | HLA class I histocompatibility antigen, B alpha chain | 0.705 | P67870 | CSNK2B | Casein kinase II subunit beta | P10321 | HLA-C | HLA class I histocompatibility antigen, C alpha chain | 0.705 | P67870 | CSNK2B | Casein kinase II subunit beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P0DP23 | CALM1 | Calmodulin-1 | 0.822 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.84 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.834 | P67870 | CSNK2B | Casein kinase II subunit beta | P17612 | PRKACA | cAMP-dependent protein kinase catalytic subunit alpha | 0.75 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.799 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | P67870 | CSNK2B | Casein kinase II subunit beta | P18848 | ATF4 | Cyclic AMP-dependent transcription factor ATF-4 | 0.733 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 |
| Talazoparib | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | | Talazoparib | hsa05166 | Human T-cell leukemia virus 1 infection | 7.39E-03 | 7 | Q9Y490, P01889, P10321, P05141, P12236, P17612, P18848 | TLN1, HLA-B, HLA-C, SLC25A5, SLC25A6, PRKACA, ATF4 | More | | Talazoparib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.02E-02 | 4 | P01889, P10321, P62873, Q29983 | HLA-B, HLA-C, GNB1, MICA | More | | Talazoparib | hsa05169 | Epstein-Barr virus infection | 3.72E-02 | 6 | Q13547, P42338, P07948, Q13761, O75293, P07766 | HDAC1, PIK3CB, LYN, RUNX3, GADD45B, CD3E | More | | Talazoparib | hsa05202 | Transcriptional misregulation in cancer | 7.84E-03 | 8 | Q12778, Q13315, Q15744, P08069, P46527, P05164, P08246, Q9C0K0 | FOXO1, ATM, CEBPE, IGF1R, CDKN1B, MPO, ELA2, BCL11B | More | | Talazoparib | hsa05203 | Viral carcinogenesis | 3.47E-05 | 9 | P18848, P30279, Q13547, Q15283, P01889, P10321, P17612, P62807, O60814 | ATF4, CCND2, HDAC1, RASA2, HLA-B, HLA-C, PRKACA, HIST1H2BC, H2BC12 | More | | Talazoparib | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Talazoparib | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa05206 | MicroRNAs in cancer | 2.41E-03 | 10 | P46527, P30279, Q9Y4H2, Q9UM47, P16070, Q13547, Q13315, P17252, P19174, Q02750 | CDKN1B, CCND2, IRS2, NOTCH3, CD44, HDAC1, ATM, PRKCA, PLCG1, MAP2K1 | More | | Talazoparib | hsa05210 | Colorectal cancer | 3.43E-02 | 2 | Q9UKG1, P37173 | APPL1, TGFBR2 | More | | Talazoparib | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Talazoparib | hsa05224 | Breast cancer | 1.24E-02 | 5 | P08069, P49841, Q92837, P04637, P24522 | IGF1R, GSK3B, FRAT1, TP53, GADD45A | More | | Talazoparib | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | Talazoparib | hsa05231 | Choline metabolism in cancer | 2.60E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | Talazoparib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.55E-02 | 5 | O95267, P09693, O60603, Q16539, P01730 | RASGRP1, CD3G, TLR2, MAPK14, CD4 | More | | Talazoparib | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Talazoparib | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Talazoparib | hsa05415 | Diabetic cardiomyopathy | 4.23E-02 | 2 | P30405, P37173 | PPIF, TGFBR2 | More | | Talazoparib | hsa05418 | Fluid shear stress and atherosclerosis | 1.26E-04 | 8 | Q16539, Q14145, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | | |